As of 31 Dec 2025, 45 institutional investors reported holding $495,372,450 in principal (par value) of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $495,372,450 | $946,553,069 | -$11,256,841 | 188.78% | 45 |
| 2025 Q3 | $503,553,600 | $706,927,628 | -$1,701,713 | 140.31% | 45 |
| 2025 Q2 | $562,169,600 | $702,425,663 | +$36,426,925 | 124.6% | 44 |
| 2025 Q1 | $574,937,600 | $656,979,517 | +$27,477,843 | 114.27% | 44 |
| 2024 Q4 | $562,886,600 | $590,898,608 | -$57,357,159 | 104.83% | 43 |
| 2024 Q3 | $580,126,900 | $598,911,587 | +$11,941,965 | 103.04% | 42 |
| 2024 Q2 | $569,382,900 | $575,758,559 | +$8,898,618 | 101.01% | 41 |
| 2024 Q1 | $560,289,110 | $603,033,697 | +$6,351,656 | 107.59% | 40 |
| 2023 Q4 | $553,225,000 | $670,007,473 | +$16,902,300 | 120.84% | 45 |
| 2023 Q3 | $544,512,610 | $527,468,975 | +$46,272,601 | 96.09% | 41 |
| 2023 Q2 | $508,797,285 | $400,809,379 | -$17,145,882 | 78.3% | 33 |
| 2023 Q1 | $24,428,285 | $29,769,764 | -$9,378,870 | 7329.41% | 5 |
| 2022 Q4 | $532,657,035 | $235,817,609 | -$942,915 | 45.0% | 31 |
| 2022 Q3 | $391,715,535 | $242,598,365 | +$158,207 | 59.28% | 31 |
| 2022 Q2 | $403,210,035 | $228,835,958 | -$80,860,371 | 54.6% | 31 |
| 2022 Q1 | $546,513,489 | $332,288,737 | -$4,271,771 | 58.89% | 33 |
| 2021 Q4 | $522,000,515 | $380,362,858 | -$37,345,964 | 73.22% | 38 |
| 2021 Q3 | $532,460,742 | $739,286,875 | -$47,139,012 | 138.21% | 40 |
| 2021 Q2 | $570,332,000 | $936,089,296 | +$76,483,812 | 164.13% | 39 |
| 2021 Q1 | $519,285,000 | $858,858,248 | +$842,687,530 | 165.39% | 35 |